AdvaGene Biopharma Co. Ltd.
Clinical trials sponsored by AdvaGene Biopharma Co. Ltd., explained in plain language.
A biopharmaceutical company developing gene therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Nasal spray could tame tough asthma Flare-Ups Results expected Oct 2026 (estimated)
-
Nasal spray shows promise for tough asthma in early trial
Disease control CompletedThis study tested an experimental nasal spray called AD17002 in 40 adults with poorly controlled moderate-to-severe eosinophilic asthma. Participants self-administered the spray twice a week for six weeks. The goal was to see if it could improve lung function and reduce the need …
Phase 1/2 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:35 UTC
-
New nasal spray aims to sneeze away dust mite allergies
Symptom relief CompletedThis study tested a nasal spray called AD17002 in 48 adults with house dust mite allergic rhinitis. The goal was to see if it is safe and can reduce symptoms like sneezing, runny nose, and congestion. Participants received either the spray or a placebo, and researchers monitored …
Phase 1/2 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Symptom relief
Last updated Jun 26, 2026 17:38 UTC